Other tumor-type-specific “druggable” genes included EPHA4, AVPR1B, CACNA2D2, AR, CCL3 and PTGER4 in ACTH-secreting adenomas; SLIT1, BRCA2, DYRK1B, GHSR, and GRM5 in GH-secreting adenomas; SLIT1, KCNH8, GRM5, GRIN3A and NRG1 in prolactinomas; SLIT1, SSTR2, KCNA4, KCNQ5, GRIA1, and GRIA3 in TSH-secreting adenomas; and SLIT1, KCNH8, GRM5, GRIN3A, NRG1 in prolactinomas. Here, BRCA2 is linked to neoplasm.